OPTIMIZE 以患者和家庭为中心的基层医疗减处方干预:务实整群随机对照试验方案
该方案针对痴呆或轻度认知障碍合并多种慢病的老年人,在Kaiser Permanente Colorado的基层诊所开展务实整群随机试验,评估以患者和家庭为中心的减处方干预能否减少慢性药物与潜在不适当药物数量。预计约2400例患者接受干预,另9家诊所作为等待名单对照,主要结局为慢性药物总数和PIM总数。
要点
- 干预同时教育并激活患者、家庭成员和基层医生,推动减处方。
- 主要结局为慢性药物总数与潜在不适当药物(PIM)总数。
- 目标人群为服用5种及以上药物的痴呆或MCI合并多种慢病老年人。
核心结论
- 该试验将检验以基层医疗为基础、以患者和家庭为中心的减处方干预能否减少痴呆或MCI合并多种慢病老年人的慢性药物和PIM数量。
研究设计与样本
- 务实整群随机对照试验,在Kaiser Permanente Colorado开展,9家诊所实施干预,另9家诊所作为等待名单对照。
- 预计约2400例患者接受干预,对照组纳入数量相当的患者;入组对象为服用5种及以上药物的痴呆或MCI合并多种慢病患者。
主要发现
- 原文为研究方案,未报告干预效果结果。
- 把握度计算:检测平均减少-0.70种药物(不足1种药物)的把握度超过80%。
关键数值与推荐
- 主要结局为慢性药物总数和PIM总数。
- 次要结局包括PIM新启用数量、特定PIM(苯二氮䓬类、阿片类和抗精神病药)的剂量降低、不良药物事件(跌倒、出血事件和低血糖事件)发生率、日常生活活动能力,以及 skilled nursing facility、医院和急诊入院。
临床怎么用
- 干预包含患者/家庭组件(教育并激活其对减处方潜在价值的认识)和医生组件(提高医生对减处方选项与流程的认识)。
- 适合在基层医疗中对多重用药的痴呆或MCI合并多种慢病老年人开展以患者和家庭为中心的减处方管理。
局限性
- 原文为研究方案,尚无干预效果数据。
- 试验注册号为NCT03984396,注册日期2019年6月13日。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most individuals with dementia or mild cognitive impairment (MCI) have multiple chronic conditions (MCC). The combination leads to multiple medications and complex medication regimens and is associated with increased risk for significant treatment burden, adverse drug events, cognitive changes, hospitalization, and mortality. Optimizing medications through deprescribing (the process of reducing or stopping the use of inappropriate medications or medications unlikely to be beneficial) may improve outcomes for MCC patients with dementia or MCI. METHODS: With input from patients, family members, and clinicians, we developed and piloted a patient-centered, pragmatic intervention (OPTIMIZE) to educate and activate patients, family members, and primary care clinicians about deprescribing as part of optimal medication management for older adults with dementia or MCI and MCC. The clinic-based intervention targets patients on 5 or more medications, their family members, and their primary care clinicians using a pragmatic, cluster-randomized design at Kaiser Permanente Colorado. The intervention has two components: a patient/ family component focused on education and activation about the potential value of deprescribing, and a clinician component focused on increasing clinician awareness about options and processes for deprescribing. Primary outcomes are total number of chronic medications and total number of potentially inappropriate medications (PIMs). We estimate that approximately 2400 patients across 9 clinics will receive the intervention. A comparable number of patients from 9 other clinics will serve as wait-list controls. We have > 80% power to detect an average decrease of - 0.70 (< 1 medication). Secondary outcomes include the number of PIM starts, dose reductions for selected PIMs (benzodiazepines, opiates, and antipsychotics), rates of adverse drug events (falls, hemorrhagic events, and hypoglycemic events), ability to perform activities of daily living, and skilled nursing facility, hospital, and emergency department admissions. DISCUSSION: The OPTIMIZE trial will examine whether a primary care-based, patient- and family-centered intervention educating patients, family members, and clinicians about deprescribing reduces numbers of chronic medications and PIMs for older adults with dementia or MCI and MCC. TRIAL REGISTRATION: NCT03984396. Registered on 13 June 2019.
引用
- Bayliss EA, Shetterly SM, Drace ML, et al. The OPTIMIZE patient- and family-centered, primary care-based deprescribing intervention for older adults with dementia or mild cognitive impairment and multiple chronic conditions: study protocol for a pragmatic cluster randomized controlled trial. Trials. 2020. PMID: 32552857. doi:10.1186/s13063-020-04482-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。